Frontline immunotherapy for NSCLC: alone or not alone?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/s41571-018-0070-7.pdf
Reference12 articles.
1. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
2. Lopes, G. et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced metastatic NSCLC with a PD-L1 tumor proportion score ≥1%: open-label, phase 3 KEYNOTE-042 study [abstract]. J. Clin. Oncol. 36 (Suppl.), LBA4 (2018).
3. Langer, C. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced non-squamous, non-small-cell lung cancer: a randomized phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).
4. Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
5. Paz-Ares, L. et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (chemo) with or without pembrolizumab (pembro) for metastatic squamous (sq) non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 36 (Suppl), 105 (2018).
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19;Frontiers in Immunology;2024-09-06
2. Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide;Nano Research;2023-11
3. Natural Cyclophilin A Inhibitors Suppress the Growth of Cancer Stem Cells in Non-Small Cell Lung Cancer by Disrupting Crosstalk between CypA/CD147 and EGFR;International Journal of Molecular Sciences;2023-05-29
4. From targeted therapy to a novel way: Immunogenic cell death in lung cancer;Frontiers in Medicine;2022-12-23
5. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis;Frontiers in Pharmacology;2021-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3